Verdict94/ 100
Grade A · #1CoreAge Rx
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxHead-to-head verdict
CoreAge Rx vs Bon Health
Two GLP-1 providers, ruled side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
vs
Verdict60/ 100
Grade C · #327Bon Health
Bon Health is a physician-led GLP-1 weight-loss telehealth service offering compounded semaglutide and tirzepatide on transparent commitment tiers — from $170/mo on the annual plan up to $330 month-to-month…
Visit Bon HealthThe verdict
Winner: CoreAge Rx
CoreAge Rx takes it with a higher Verdict Score — 94/100 to 60/100 (grade A vs C). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. Bon Health still earns its place — shoppers wanting transparent, no-membership compounded GLP-1 with physician-titrated dosing.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
92Real-world results75
92
Real-world results75
97Price honesty40
97
Price honesty40
96Prescriber access46
96
Prescriber access46
88Formulary choice45
88
Formulary choice45
95Cancellation fairness82
95
Cancellation fairness82
93Member support84
93
Member support84
Price, coverage & features
| Metric | CoreAge Rx | Bon Health |
|---|---|---|
| Verdict Score | 94/100 | 60/100 |
| Grade | A | C |
| Semaglutide | $149/mo | From $120/mo (12-mo plan, compounded) |
| Tirzepatide | $349/mo | From $170/mo (12-mo plan, compounded) |
| Coverage | All 50 states | Not disclosed |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | No | No |
CoreAge Rx
What we like
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation
The caveats
- Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Bon Health
What we like
- Transparent commitment-tier pricing from $170/mo (annual) for compounded semaglutide and tirzepatide; $0 membership fee, cancel anytime
- Physician-led: comprehensive medical review and physician-titrated dosing, not a 2-minute quiz
- 24/7 physician support included free with your order; 1-3 day rapid dispatch
- Licensed in all 50 states; uses 503A & 503B compounding pharmacies; brand-name Wegovy/Ozempic/Zepbound/Mounjaro also offered
The caveats
- The advertised rates need a full year paid up front; billed monthly, semaglutide is $230 and the annual figure nearly doubles
- The brand-name pages are marketing, not products — every Wegovy, Ozempic, Zepbound and Mounjaro CTA reads 'Coming Soon' and points back to the compounded version
- Coverage is not published: a badge claims all 50 states while the weight-loss page says availability varies by state
- The terms page returns a 404, so the refund mechanics behind the prepaid 3-, 6- and 12-month tiers cannot be read
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Also worth a look
Shoppers wanting transparent, no-membership compounded GLP-1 with physician-titrated dosing.
Visit Bon Health Read the full Bon Health review →Keep comparing
Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programmes closest to it, and the same shortlist for Bon Health does the reverse.
Or browse the full comparison hub and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.